Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Exclusion Criteria

• •Use of any medication (prescription, over-the-counter, herbal tea, or supplements) within 7 days of dosing
• •Use of any investigational agent or study treatment within 30 days of Day -1
• •Use of any protein or antibody-based therapeutic agents within 3 months of Screening
• •Prior exposure to LX4211 or canagliflozin
• •Daily use of \>5 cigarettes or any tobacco products within 6 weeks prior to Screening and while participating in the study
• •History of bariatric surgery or any other gastrointestinal surgery that may induce malabsorption
• •History of bowel resection, any malabsorptive disorder, severe gastroparesis, any GI procedure for the purpose of weight loss which would slow gastric emptying
• •History of any major surgery within 6 months prior to Screening
• •History of any hypersensitivity to the inactive components of LX4211, inactive components of canagliflozin, acetaminophen oral solution or any inactive component of acetaminophen liquid preparation
• •History of renal disease or significantly abnormal kidney function tests
• •History of hepatic disease or significantly abnormal liver function tests
• •History of any active infection within 30 days prior to Day -1
• •History of alcohol or substance abuse within 2 years prior to Day 1
• •History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1 or HIV-2
• •Donation or loss of \>500 mL of blood or blood product within 56 days of Day -1
• •positive pregnancy test at Screening or Day -1
• •Positive urine screen for drugs of abuse at Screening or Day -1
• •Positive breath test for alcohol at Screening or Day -1
• •Inability or difficulty swallowing whole tablets
• •Unable or unwilling to communicate or cooperate with the Investigator